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Introduction
Homeobox proteins comprise a large family of tran-
scription factors that contain a highly conserved
60–amino acid DNA binding domain (homeodomain
[HD]) (1, 2). Csx/Nkx2.5 belongs to the NK2 class of
homeobox proteins characterized by a tyrosine residue
at amino acid 54 of the HD (54Tyr in HD) and a con-
served 23–amino acid NK2-specific domain (3–5).
NK2 class HD proteins are expressed in a tissue-spe-
cific manner and are important for the determination
of cell fate. Csx/Nkx2.5 is the earliest known marker of
the heart field mesoderm in Drosophila, zebrafish,
Xenopus, chick, and mouse and is shown to be essential
for heart formation in Drosophila, Xenopus, and mouse
(6–12). In mice, Csx/Nkx2.5 expression starts as early
as 7.5 days postcoitum (dpc) in the precardiac meso-
derm and its expression continues throughout adult-
hood (13–15). Csx/Nkx2.5-targeted homozygous
mutant mice show normal heart tube formation, but
die around 11 dpc before or just after completion of
looping morphogenesis (11, 12). Analysis of
Csx/Nkx2.5 homozygous mutant embryos showed
downregulation of ventricular myosin light chain 2V, atri-
al natriuretic factor (ANF), and brain natriuretic factor, but
most myofilament genes are normally expressed. Tran-
scription factors including eHAND, MEF2C, N-Myc,
CARP, Msx2, and Irx4 are downregulated or misex-
pressed in the mutant embryo (11, 12, 16–19).
In Xenopus and zebrafish, overexpression of wild-type
Nkx2.5 causes cardiac enlargement due to an increase
in the number of cardiac myocytes (8, 20, 21). On the
other hand, dominant inhibitory mutants of Xenopus
XNkx2.3 as well as XNkx2.5, created either by fusion to
the engrailed repressor domain or by mutating a single
amino acid within the HD to abolish DNA binding,
causes small hearts or in the most severe case, a com-
plete loss of heart in Xenopus embryos (9, 10).
Recently, heterozygous mutations of human
CSX/NKX2.5 were identified in patients with congen-
ital heart disease (22, 23). The most common pheno-
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CSX/NKX2.5 is an evolutionarily conserved homeodomain-containing (HD-containing) transcrip-
tion factor that is essential for early cardiac development. Recently, ten different heterozygous
CSX/NKX2.5 mutations were found in patients with congenital heart defects that are transmitted in
an autosomal dominant fashion. To determine the consequence of these mutations, we analyzed
nuclear localization, DNA binding, transcriptional activation, and dimerization of mutant
CSX/NKX2.5 proteins. All mutant proteins were translated and located to the nucleus, except one
splice-donor site mutant whose protein did not accumulate in the cell. All mutants that had trunca-
tion or missense mutations in the HD had severely reduced DNA binding activity and little or no tran-
scriptional activation function. In contrast, mutants with intact HDs exhibit normal DNA binding
to the monomeric binding site but had three- to ninefold reduction in DNA binding to the dimeric
binding sites. HD missense mutations that preserved homodimerization ability inhibited the acti-
vation of atrial natriuretic factor by wild-type CSX/NKX2.5. Although our studies do not character-
ize the genotype-phenotype relationship of the ten human mutations, they identify specific abnor-
malities of CSX/NKX2.5 function essential for transactivation of target genes.
J. Clin. Invest. 106:299–308 (2000).
type was progressive atrioventricular conduction delays
(AV block) and secundum atrial septal defect (ASD),
but other anatomical abnormalities, such as ventricu-
lar septal defect (VSD), tetralogy of Fallot (TOF), or tri-
cuspid valve abnormalities including Ebstein’s anom-
aly, and progressive left ventricular failure were also
found (22, 23). These findings strongly suggest that
CSX/NKX2.5 is important in the later stages of heart
development and maturation in addition to its func-
tions in early cardiac development.
To date, a number of mutations in HD proteins have
been identified in a variety of congenital disorders;
however, only CSX/NKX2.5 mutations have been iden-
tified in the NK2 class associated with congenital dis-
ease (24–26). Most of these mutations are point muta-
tions in exons (nonsense or missense) or in RNA
splicing signals. Others are small nucleotide insertions
or deletions that cause intron-splicing abnormalities or
produce frameshifts leading to truncated proteins. Sev-
eral biochemical studies showed that the mutant
homeoproteins may function as either loss of function
or dominant inhibitory mutants (25–29). However, the
mechanisms by which CSX/NKX2.5 mutations cause
congenital heart disease have not been defined. Here,
we report the initial biochemical characterization of
ten different CSX/NKX2.5 mutations associated with
human congenital heart disease.
Methods
Plasmid construct. pBS SK(-)-CSX/NKX2.5 (ref. 30) digest-
ed with BglI-blunt–ended and EcoRI was ligated into
SacI-blunt–ended and EcoRI-digested pMALC2 (New
England Biolabs Inc., Beverly, Massachusetts, USA) to
construct maltose binding protein–CSX/NKX2.5
(MBP-CSX/NKX2.5). BglI-blunt–ended and XhoI-
digested pBS SK(-)-CSX/NKX2.5 was ligated into
EcoRV-XhoI-digested pcDNA3 (Invitrogen Corp., San
Diego, California, USA) to construct pcDNA3-
CSX/NKX2.5. FLAG epitope tag (gac tac aaa gac gat
gac gac aag) was inserted at the NH2-terminus of
pcDNA3-CSX/NKX2.5. Site-directed mutations were
introduced into both plasmids by using Quick Change
Site-Directed Mutagenesis Kit (Stratagene, La Jolla,
California, USA) with the following primers:
M25 (F, 5′-AACAGCAGCAGtGCAGCCTGGCT-3′; 
R, 5′-AGCCAGGCTGCaCTGCTGCTGTT-3′): 
M149 (F, 5′-TTCTCGCAGGCGtAGGTCTATGAGCT-3′; 
R, 5′-AGCTCATAGACCTaCGCCTGCGAGAA-3′): 
M170 (F, 5′-CGAACGCGACtAGCTGGCCAGC-3′; 
R, 5′-GCTGGCCAGCTaGTCGCGTTCG-3′): 
M178 (F, 5′-TGCTGAAACTCAtGTCCACGCAGG-3′; 
R, 5′-CCTGCGTGGACaTGAGTTTCAGCA-3′): 
M188 (F, 5′-TGGTTCCAGAAaCGGCGCTACAA-3′; 
R, 5′-TTGTAGCGCCGtTTCTGGAACCA-3′): 




M198 (F, 5′-AAGCGGCAGCGGtAGGACCAGACT-3′; 
R, 5′-AGTCTGGTCCTaCCGCTGCCGCTT-3′): 
M259 (F, 5′-CTATCCGGGTTAaGGCGGCGCGGCCT-3′; 
R, 5′-AGGCCGCGCCGCCtTAACCCGGATAG-3′). 
pcDNA3-CSX/NKX2.5 was digested with pflMI-NotI,
blunt ended and religated to construct pcDNA3-
CSX/NKX2.5(1-200).
The SphI-KpnI fragment of CSX/NKX2.5 genomic
clone (hCsx10) was inserted into SphI-KpnI-digested
MBP-CSX/NKX2.5 to construct MBP-hCsx10. A muta-
tion was introduced by site-directed mutagenesis using
5′-CCGAAAAGAAAGtTGAGGAGGAA-3′; 5′-TTCCTCCT-
CAaCTTTCTTTTCGG-3′) to construct MBP-M112. PmlI-
PflMI-digested fragments of MBP-hCsx10 and MBP-
M112 were replaced with that of pcDNA3-CSX/NKX2.5
to construct pcDNA3-hCsx10 and pcDNA3-M112. All
the PCR-amplified fragments were sequenced to rule
out DNA misincorporations.
Electrophoretic mobility shift assay. MBP fusion proteins
were prepared as described previously (31). Briefly, cul-
tured Escherichia coli BL21(DE3) (Novagen, Madison,
Wisconsin, USA) induced with 0.3 mM of IPTG, were
lysed by sonication in lysis buffer (20 mM HEPES [pH
7.5], 100 mM NaCl, 5 mM MgCl2, 1% Triton X-100, 2
µg/mL aprotinin, 0.7 µg/mL pepstatin, 0.1 mM PMSF,
1 mM DTT, and 10% glycerol), and lysates were incu-
bated with amylose resin (New England Biolabs Inc.).
Fusion proteins were eluted from the beads with lysis
buffer (0.1% Triton X-100 instead of 1%) containing 10
mM maltose. The molecular weight of MBP fusion pro-
tein was estimated by the addition of the molecular
weight of MBP protein (mol wt = 42 kDa) and full
length (mol wt = 34.9 kDa) or M198 (mol wt = 22.1
kDa) or M259 (mol wt = 28.5 kDa) or M25 (mol wt =
34.9 kDa). Of note, MBP-fused CSX/NKX2.5 proteins
do not remain completely intact during purification.
Coomassie stained SDS-PAGE gel was scanned and the
intensity of the top bands representing the intact pro-
teins were compared with that of the BSA standard to
estimate the protein concentration.
2 pM of end-labeled ANF Csx/Nkx2.5 binding site, 5′-
– 2 6 4 T C A C A C C T T T G A A G T G G G G G C C T C T T G A G -
GCAAATC–227-3′ was annealed with 5′-GATTTGCCTCAA-
GAGGCCCCCACTTCAAAGGTGTGA-3′, and 5′- –264TCA-
CACCTTTGAAGTGGGGGCCT-3′ was annealed with
5′-AGGCCCCCACTTCAAAGGTGTGA-3′ and used for elec-
trophoretic mobility shift assay (EMSA). Threefold seri-
al dilutions of 66 ng of bacterially expressed fusion pro-
teins were incubated with 50,000 cpm of probe, 50 µg
BSA, 0.5 µg poly (dG-dC) in 10 mM HEPES (pH 8.0),
50 mM KCl, 1 mM EGTA, 10% glycerol, 2.5 mM DTT,
and 7 mM MgCl2 in 15 µL reaction volume for 20 min-
utes at room temperature, separated in 5% polyacry-
lamide gel with 0.5 × Tris-glycine buffer at 15 mA for
approximately 20 minutes.
Reporter gene assays. 10T1/2 fibroblast cells cultured in
six-well plates were transfected with 1.5 µg of ANF-
luciferase reporter construct (–638, provided by K.R.
Chien, University of California at San Diego, La Jolla, Cal-
ifornia, USA), 1 µg of pcDNA3-CSX/NKX2.5 expression
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vector and 0.5 µg of Rous sarcoma virus–β-galactosidase
(RSV–β-galactosidase) (provided by B. Markham) using
the calcium phosphate method. Total plasmid amount
was adjusted to 3 µg with pcDNA3 vector plasmid. For
cotransfection experiments, 1.2 µg of ANF-luciferase
reporter construct, 0.3 µg of RSV–β-galactosidase con-
struct, 0.7 µg of pcDNA3-CSX/NKX2.5 expression vec-
tor, 0.7 or 1.4 µg of pcDNA3 expression vector encoding
mutant proteins and pcDNA3 empty vector to adjust the
total plasmid amount 3.6 µg were used. After glycerol
shock using 1X HEPES buffer containing 15% glycerol,
cells were cultured for another 48 hours, lysed with 300
µL of reporter lysis buffer (Promega Corp., Madison, Wis-
consin, USA) and assayed for luciferase activity (Promega
Corp.) and β-galactosidase activity.
Protein-protein interaction. Bacterially produced MBP-
CSX/NKX2.5, MBP, glutathione-S-transferase-GATA4
(GST-GATA4; provided by D. Wilson) and GST protein
were made as described previously (31). In vitro-tran-
scribed and translated proteins were generated by using
TNT-coupled reticulocyte lysate systems (Promega
Corp.). A total of 1 µL of reticulocyte lysate containing
[35S]-labeled wild-type or mutant CSX/NKX2.5 pro-
teins was mixed with the fusion proteins bound on the
beads in 400 µL of binding buffer (20 mM HEPES [pH
7.5], 100 mM NaCl, 5 mM MgCl2, 0.1% Triton X-100,
aprotinin [2 µg/mL], pepstatin [0.7 µg/mL], 0.1 mM
PMSF, 1 mM DTT, and 1% BSA) at 4°C for 2 hours.
Beads were washed with binding buffer (without BSA)
five times and the bound protein complexes were sub-
jected to SDS-PAGE.
Splicing assays, RT-PCR and protein synthesis assay. Tran-
sient transfection of pcDNA3-CSX/NKX2.5 wild-type
and various mutants in COS 7 cells was performed by
using Lipofectamine (GIBCO BRL, Gaithersburg, Mary-
land, USA) as described previously (15). Cells on 6 cm
plates were harvested approximately 24 hours after
transfection, spun down and directly lysed in 200 µl of
SDS-PAGE sample buffer (62.5 mM Tris [pH 6.8], 2.3%
SDS, 10% glycerol, 5% 2-mercaptoethanol), and 20 µL of
protein (∼ 10 µg) was analyzed for protein expression by
Western blotting using anti-FLAG mAb (Sigma Chemi-
cal Co., St. Louis, Missouri, USA), anti-Csx/Nkx2.5 mAb
(15) and anti-GAPDH mAb (RDI Research Diagnostics
Inc., Flanders, New Jersey, USA). Total RNA was extract-
ed from transfected cells (RNeasy kit; Qiagen Inc., Valen-
cia, California, USA), and 0.5 µg were used for RT-PCR
(Perkin-Elmer Corp., Norwalk, Connecticut, USA) by the
use of a sense primer (5′-CAAGGACCCTAGAGCCGAAAAG-
3′) and an antisense primer (5′-TTGACCTGCGTGGACGT-
GAGTTTC-3′) for CSX/NKX2.5 that span the intron. In
vitro transcription/translation was performed using the
TNT-coupled reticulocyte lysate system (Promega Corp.)
using 2 µg plasmid/ 50 µL reaction.
Results
Grouping of ten mutants according to predicted protein struc-
ture. Human CSX/NKX2.5 is a 324–amino acid protein,
that includes an HD between amino acids 138 and 197
(30, 32) and an Arg-Lys cluster of a nuclear localization
signal at the NH2-terminus of the HD (Figure 1) (31).
Ten mutation sites identified in patients (22, 23) (Fig-
ure 1, asterisks) are distributed throughout the
CSX/NKX2.5 molecule. Two mutations are located at
the NH2-terminus to the HD, six are within the HD,
and two are located COOH-terminus to the HD. As
shown in Figure 1, these mutation sites were divided
into five groups based on the predicted protein struc-
ture: group 1: two nonsense mutations in the HD
(M149 and M170); group 2: four missense mutations
within the HD [178Thr-Met (M178), 188Asn-Lys (M188),
189Arg-Gly (M189), and 191Tyr-Cys (M191)]; group 3:
two truncation mutants occurring COOH-terminal to
the HD [∆198-324 (M198) and ∆259-324 (M259)];
group 4: one missense mutation NH2-terminal to the
HD (25Arg-Cys, M25); and group 5: one point mutation
at the exon-intron splicing site (M112). The corre-
sponding phenotype associated with each of these
mutations is indicated in Figure 1 (23).
All mutant proteins were translated and localized to the
nucleus, except one splice-donor site mutant protein (M112)
that did not accumulate in the cell. To determine whether
mutant proteins accumulate in the cell, FLAG epitope
tagged mutant cDNAs were subcloned into the mam-
malian expression vector pcDNA3 and transfected into
COS cells. By Western blotting using anti-FLAG mAb
(Figure 2a), proteins with expected molecular weight
were detected in group 1, 2, 3 and 4 mutants, whereas
group 5 (M112) mutant protein was not detected. As
shown in Figure 2b, all accumulated proteins were
localized in the nucleus.
The M112 expression construct contained a mutat-
ed intron (G→T transversion) involving the first
nucleotide of the splice-donor site and results in a
change in sequence from GTGAGG to TTGAGG (Fig-
ure 2c). To examine whether the failure of protein
accumulation in cells is due to transcriptional or
translational regulation, we compared mRNA and
protein expression in transfected cells. As a control,
we inserted the wild-type intron (1,539 bp) in the
wild-type cDNA construct used in Figure 2a. RNA iso-
lated from transfected cells was amplified by RT-PCR
with two primers spanning the intron. The wild-type
construct amplified a major spliced product (240 bp)
with a low amount of nonspliced product (1,779 bp).
In contrast, RT-PCR of RNA isolated from cells trans-
fected with the M112 construct produced only the
nonspliced product (1,779 bp). In wild-type transfec-
tants, CSX/NKX2.5 protein was detected as a 42-kDa
band by both anti-FLAG mAb and the anti-
Csx/Nkx2.5 mAb (Figure 2d, left, lane 1). However,
M112 protein was not detected (Figure 2d, left, lane
2), even though the corresponding mRNA was as eas-
ily detected by RT-PCR as that of wild-type (Figure
2c). In vitro transcription and translation of M112
produced a protein with an approximate molecular
eight of 29 kDa (Figure 2d, right, lane 2), but in the
cell, the translation product did not accumulate.
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Thus, it is likely that the M112 allele functions as a
heterozygous null allele in vivo.
Assessment of mutant DNA binding using EMSA. We exam-
ined DNA binding affinity by using the electrophoretic
mobility shift assay (EMSA). The ANF promoter, an in
vivo Csx/Nkx2.5 target, contains three specific
Csx/Nkx2.5 binding sites (TNAAGTG) (3, 33) that are
located upstream of the transcription start site at
approximately –408, –242, and –87 bp (34, 35). We used
the –242 bp binding site as a probe to examine
CSX/NKX2.5 binding affinity, since this site contains
two binding sites spaced by 5 nucleotides for
CSX/NKX2.5 (Figure 3a) and had more than 80-fold
higher affinity than the -87 bp site (data not shown).
The [32P]-labeled 32 bp oligonucleotide of the ANF pro-
moter (–248 to –217, ANF –242) was mixed with wild-
type or a mutant protein purified from E. coli as an MBP
fusion protein (Figure 3b). In each panel, lane 1 shows
free DNA probe without protein (F), and lanes 2–7 show
threefold serial increase in protein concentration
(0.018–4.4 µg/mL) mixed with the same amount of
DNA probe. The wild-type CSX/NKX2.5 formed two
specifically shifted bands in each lane (Figure 3b, wild).
The faster migrating band most likely corresponds to
the occupation of one of the two specific DNA binding
sites of the ANF –242 (M, monomer), and the slower
migrating band, to the simultaneous occupation of the
two DNA binding sites (D, dimer). The intensity of
these bands was dependent on the protein concentra-
tion of CSX/NKX2.5 in the reaction (Figure 3b, wild).
Group 1 and group 5 do not bind DNA due to the lack of the
third helix of HD. As expected, group 1 mutant proteins
(M149 and M170) with truncated HD did not bind
DNA (Figure 3b, group 1). Similarly, the mutant MBP
fusion protein M112 (group 5), which does not encode
HD, did not bind DNA (Figure 3b, group 5).
Group 2 mutants have markedly reduced DNA binding
affinity. Four mutants that have a single missense muta-
tion in the HD comprise group 2 (Figure 3c); all group
2 mutants had markedly reduced DNA binding affini-
ty. 178Thr-Met (M178) mutation is located just before
the third helix of the HD. 178Thr-Met (M178) mutation
required approximately 34-fold (81-fold) higher protein
concentration to shift the DNA probe to the same
degree as wild-type. 188Asn (amino acid 51 in HD) that
is conserved among all the HD proteins and is critical
for DNA binding (1, 2). 188Asn-Gly (M188) mutant had
more than 35-fold (273)-fold lower DNA binding affin-
ity than wild-type. Also, 189Arg-Gly (M189) mutation
showed barely detectable DNA binding. The 191Tyr
residue (54Tyr in HD) is unique for the NK2 class HD
proteins (3–5, 8). 191Tyr-Cys (M191) mutant protein
also showed a markedly reduced DNA binding affinity
by approximately 34-fold (81-fold) (Figure 3c).
Group 3 and group 4 mutants showed similar DNA binding
affinity as a monomer but reduced DNA binding affinity as a
dimer. In three mutants, the HD was unaffected; two
COOH-terminus deletion mutants (M198 and M259)
comprised group 3, and an NH2-terminus missense
mutation (M25) comprised group 4. All group 3 and 4
mutant proteins bound to DNA (Figure 4), but there
were subtle but significant differences in DNA binding
characteristics. CSX/NKX2.5 bound to the dimeric NK2
specific binding sites predominantly as a monomer at a
low protein concentration and transited into a dimer at
higher protein concentration. In wild-type CSX/NKX2.5
protein, the monomer-dimer transition was observed in
lane 3 (Figure 4a, asterisk in wild-type) at an approximate
protein concentration of 0.055 µg/mL or 7.1 × 10–10 M).
In contrast, M198 required approximately 9 (32) times
higher protein concentration to yield a monomer/dimer
ratio similar to that of wild-type (Figure 4b, asterisk in
M198; approximate protein concentration 7.7 × 10–9 M).
A 31–32 times higher protein concentration was necessary
for equimolar monomer-dimer formation in M259 (Fig-
ure 4c, asterisk in M259; approximate protein concen-
tration 2.3 × 10–9 to 7.0 × 10–9 M). We also detected a sub-
tle defect of dimer formation in the M25 mutant, which
required approximately three times higher protein con-
centration to yield a monomer/dimer ratio similar to that
of wild-type (Figure 4d, asterisk in M25; approximate
protein concentration 2.1 × 10–9 M).
To confirm that these mutant proteins bound to the
monomeric binding site with a similar affinity, we per-
formed EMSA using oligonucleotides in which one of
the DNA binding sites was deleted from the ANF -242
site. Group 3 and group 4 mutants bound to the
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Figure 1
Diagram of CSX/NKX2.5 cDNA with the location of ten mutation
sites identified in congenital heart disease. Ten mutation sites (aster-
isks in Wild) were divided into five groups based on the predicted
protein structure: nonsense mutation in the HD (group 1: M149 and
M170); missense mutation in the HD (group 2: M178, M188,
M189, and M191); premature termination after HD (group 3: M198
and M259); 25Arg-Cys missense mutation (group 4: M25); and
mutation at the intron-splicing donor site (group 5: M112). Pheno-
types observed in patients are listed on the left. For example, “11/12”
indicates that 11 patients show the phenotype among 12 patients
examined. These mutation sites were mapped on CSX/NKX2.5
cDNA, which encodes 324 amino acids including 60 amino acids of
HD (shaded box). Nuclear localization signal at the NH2-terminus of
the HD is indicated (black box). Predicted translated product of
M112 mutation in splicing donor site is indicated with a light gray
box. AV block, atrioventricular conduction block; ASD, atrial septal
defect; VSD, ventricular septal defect; TOF, tetralogy of Fallot; TV,
tricuspid valve abnormality; DORV, double outlet right ventricle;
NLS, nuclear localization signal; HD, homeodomain.
mutated monomeric site with identical affinity as wild-
type CSX/NKX2.5 (Figure 4, e–h). These findings sug-
gest that group 3 and group 4 mutants bound to
monomeric DNA binding sites with similar affinity as
wild-type CSX/NKX2.5, but the mutations decreased
the ability to form dimers on the dimeric site.
Transcriptional activation function of CSX/NKX2.5
mutants. We examined the transcriptional activation
function using the ANF-luciferase reporter construct.
The mutants subcloned into pcDNA3 were transfected
into 10T1/2 cells with ANF luciferase reporter plasmid
(Figure 5). Wild-type CSX/NKX2.5 activated the ANF-
luciferase reporter gene 23.0 ± 2.2 fold compared with
the pcDNA3 parental vector, indicating that human
CSX/NKX2.5 is a transcriptional activator as is the
mouse Csx/Nkx2.5 (31, 33–35), which shows 87% over-
all amino acid homology (30).
As expected from the EMSA data, group 1 and group 5
(M112) with truncated HD (Figure 3b) did not activate
the ANF-luciferase reporter gene (Figure 5). Group 2
mutants, which have markedly reduced DNA binding,
also failed to activate the ANF reporter. M198 in group 3
and M25 in group 4 mutants transactivated the reporter
construct as effectively as wild-type, whereas M259 in
group 3 had a reduced transcriptional activation func-
tion (5.2 ± 0.9 fold). Because the COOH-terminus dele-
tions of the mouse Csx/Nkx2.5 were shown to cause
markedly increased transcriptional activity (31, 33), the
finding of unchanged or lower transcriptional activities
of group 3 mutants was unexpected. Accordingly, we con-
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Figure 2
Expression of translated products in cells:
intron-splicing defect in M112 mutant resulted
in poor protein accumulation. (a) Wild-type and
mutant CSX/NKX2.5 expression vectors were
transfected into COS 7 cells, and the protein
expression was examined by Western blotting
using anti-FLAG Ab approximately 24 hours
after transfection (FLAG, top). All mutant pro-
teins except M112 (lane 11, asterisk indicates
the expected molecular weight of M112 protein)
were detected at the expected molecular weight.
GAPDH expression in each lane was also shown
(GAPDH, bottom). (b) Wild-type and mutant
CSX/NKX2.5 proteins accumulated in the nucle-
us colocalizing with Hoechst nuclear staining
(NUC, lower panels). The results presented are
wild-type, group 1 (M170), group 2 (M191),
group 3 (M198), and group 4 (M25). (c) G→T
substitution (large arrow) identified in M112
mutant on the CSX/NKX2.5 splicing donor site
was examined by RT-PCR. RNA-purified form
COS 7 cells transfected with the wild-type and
M112 mutant of CSX/NKX2.5 were amplified
with two primers spanning the intron. In the
wild-type transfectant, the intron was spliced
out, resulting in the generation of 240-bp prod-
uct, whereas in the mutant transfectant, G→T
substitution of the first codon of the intron splic-
ing site abolished the normal splicing, resulting
in generation of 1,779-bp product. CSX/NKX2.5
protein was encoded by the two exons repre-
sented. (d) Translated products were examined
approximately 24 hours after transfection by
Western blotting using anti-FLAG mAb (top)
and anti-Csx/Nkx2.5 mAb (bottom). Wild-type
CSX/NKX2.5 gene was translated into approxi-
mately 42-kDa protein and was detected with
anti-FLAG and anti-Csx/Nkx2.5 mAb (lane 1). In
contrast, M112 mutant protein that is expected
to migrate approximately 29 kDa was not
detected in the cell lysate (lane 2). In in vitro
transcription and translation system, cDNA pro-
duced approximately 42-kDa protein (lane 1),
and M112 genomic construct produced about
29-kDa protein (lane 2).
structed another COOH-terminus deletion mutant,
CSX/NKX2.5(1-200) that includes an additional three
amino acid COOH-terminus to the HD and corresponds
exactly to the murine Csx/Nkx2.5(1-199) mutant and
was previously shown to have very high transcriptional
activity (240-fold) (31). Similar to the mouse mutant,
CSX/NKX2.5(1-200) had markedly increased transcrip-
tional activity (136 ± 10 fold; Figure 5). These results
demonstrate that mutants that do not encode the com-
plete HD (group 1 and group 5) or with single missense
mutation in the HD did not transactivate the ANF pro-
moter. Although CSX/NKX2.5(1-200) showed “gain of
function,” neither M198 nor M259 COOH-terminus
deletion mutants were gain-of-function mutations.
Effects of group 1, 2, 3, and 4 mutants on wild-type
CSX/NKX2.5. To examine whether these mutations
affect transcriptional activity of wild-type CSX/NKX2.5,
we cotransfected the expression plasmid encoding M170
(group 1), M189 (group 2), M191 (group 2), M259
(group 3), or M25 (group 4) with the plasmid encoding
the wild-type CSX/NKX2.5 and examined reporter gene
activity compared with that of wild-type cotransfected
with pcDNA3 empty plasmid (Figure 6a, open bar,
none). Luciferase activation after cotransfection of wild-
type with pcDNA3 empty plasmid was defined as 100%.
When the M170 protein expression plasmid was cotrans-
fected with wild-type CSX/NKX2.5 expression plasmid,
we noted an approximately 23% decrease in activation of
ANF-luciferase reporter gene compared with wild-type
alone at a plasmid ratio of 1:1 (0.7 µg) (Figure 6a,
hatched bar, M170) and 2:1 (1.4 µg) (Figure 6a, black bar,
M170). Reduction of luciferase activity was observed in
M189; 34% reduction at 1:1 ratio, and 35% reduction at
2:1 ratio, as well as in M191 (34% and 44% reduction,
respectively) and M259 (18% and 44% reduction, respec-
tively). In contrast, when the plasmid encoding the M25
mutant was cotransfected, we noted 39% increase in
luciferase activity at 1:1 ratio, and 91% increase with 2:1
ratio. These data demonstrate that cotransfection of the
plasmid-encoding groups 2 and 3 inhibited transactiva-
tion function of wild-type CSX/NKX2.5 moderately, and
further reduction of luciferase activity was observed with
cotransfection of plasmid encoding M189, M191 (group
2), and M259 (group 3) mutants, suggesting that these
mutants act in a dominant inhibitory manner on wild-
type CSX/NKX2.5 in transient transfection assays. How-
ever, these mutants did not act in a typical dominant
inhibitory manner (see Discussion). Interestingly, the
M25 mutant did not exhibit an inhibitory effect, rather
it transactivated the ANF promoter.
Protein-protein interaction of mutants with wild-type
CSX/NKX2.5. As shown in Figure 3b and Figure 4, we
found that CSX/NKX2.5 bound to the ANF -242 site as
a monomer as well as a dimer. Our recent studies
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Figure 3
DNA binding affinity of group 1, 2, and 5
mutant proteins versus wild-type CSX/NKX2.5.
(a) Sequence of two consensus CSX/NKX2.5
binding sites (–242 bp and –87 bp sites) in rat
ANF promoter; the paired binding sites in –242
bp site, and a single binding site in –87 bp site.
(b) –242 bp site was used for the DNA binding
assay (lane 1) mixed with threefold serially
increased CSX/NKX2.5 fusion proteins
(0.018–4.4 µg/mL of MBP-CSX/NKX2.5 fusion
protein) (lanes 2–7). Wild-type CSX/NKX2.5
bound as a monomer (M) as well as a dimer
(D) depending on the protein concentration.
No shifted bands were observed in groups 1
and 5 (M149, M170, and M112). (c) The
EMSA of the group 2 mutant proteins that
have a single missense mutation in the HD.
178Thr-Met (M178) mutation was located just
before the third helix, and 188Asn-Lys (M188),
189Arg-Gly (M189), and 191Tyr-Cys (M191)
were located in the third helix. Two conserved
amino acid mutations were identified: 188Asn
(51Asn in HD) is conserved in all the HD pro-
tein that is directly bound to the major groove
of DNA, and 191Tyr (54Tyr in HD) is conserved
in all NK2 class homeoprotein. All four mutant
proteins show dramatically reduced DNA bind-
ing affinity compared with the wild-type
CSX/NKX2.5. D, dimer; M, monomer; F, free
probe. Mutation sites of group 2 are indicated
with white asterisks.
demonstrated that the mouse Csx/Nkx2.5 physically
interact with each other in vitro as well as in the cell in
the absence of DNA (Kasahara et al., unpublished
data). Because DNA binding of group 2 mutants was
totally abolished or markedly reduced (Figure 3, b and
c), and these mutants themselves did not activate the
ANF promoter (Figure 5), it is of interest to examine
whether the inhibitory effect (Figure 6a) is due to dimer
formation of the mutant proteins with wild-type
CSX/NKX2.5. Accordingly, MBP-fused CSX/NKX2.5
or MBP alone were mixed with in vitro translated [35S]-
labeled mutant proteins. After extensive washing, the
protein complexes were resolved on SDS-PAGE and
autoradiographed (Figure 6b). [35S]-labeled wild-type
CSX/NKX2.5 bound to MBP-CSX/NKX2.5 fusion pro-
tein was detected in lane 1 (Figure 6b, top), but not
with MBP alone (data not shown). In contrast, group 1
(M149 and M170) and group 5 (M112) mutants did
not interact with wild-type CSX/NKX2.5 (asterisks in
lanes 2, 3, and 11), whereas group 2 (M178, M188,
M189, and M191), group 3 (M198 and M259), and
group 4 (M25) mutants interacted with CSX/NKX2.5
(lanes 4–10). Therefore, group 1 and 5 mutants, which
completely or partially lack the HD, did not associate
with wild MBP-CSX/NKX2.5, whereas mutants with
the HD associated with MBP-CSX/NKX2.5. These data
demonstrate that the HD region is necessary for dimer-
ization with wild-type CSX/NKX2.5, but the amino
acid residues mutated in group 2 mutants (amino acids
178, 188, 189, and 191) did not significantly affect the
dimer formation with wild-type CSX/NKX2.5.
Group 2 mutants can associate with GATA4 protein. Pre-
vious studies demonstrated that Csx/Nkx2.5 transac-
tivates the ANF promoter synergistically with the zinc-
finger transcription factor GATA4 (34–37). We also
demonstrated that the second zinc finger of GATA4 is
necessary and sufficient in the specific interaction
with Csx/Nkx2.5, and the third helix is required for
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Figure 4
DNA binding affinity of the group 3 and 4 mutant proteins versus wild-type CSX/NKX2.5. Sequence of the native –242 bp site (top) and
a mutated –242 bp binding site (bottom) in the ANF promoter. EMSA of group 3 (M198 and M259) and group 4 (M25, the mutation site
is marked with an asterisk) protein compared with that of the wild-type CSX/NKX2.5. Proteins were mixed with probes containing either
tandemly repeated binding sites (a–d) or single binding site (e–h). Lanes showing similar monomer/dimer ratios are indicated with aster-
isks in the top panels (a–d). In all three mutant proteins, binding affinity as a dimer is reduced approximately 3- to 32 fold (b–d versus a),
whereas they show similar DNA binding affinity as wild-type to the single binding site (f–h versus e). D, dimer; M, monomer; F, free probe.
Figure 5
Effect of ten mutations on transcriptional activation. 10T1/2 cells
were transfected with pcDNA3 expression vectors encoding wild-type
or each of ten mutations with the reporter gene ANF-luciferase.
When the wild-type CSX/NKX2.5 was transfected with the ANF
reporter gene, luciferase activity was increased 23-fold compared
with cells transfected with the empty expression vector pcDNA3.
M112, group 1, and group 2 expression vectors did not activate the
ANF promoter. M25 and M198 transactivated the reporter gene sim-
ilarly to the wild-type CSX/NKX2.5; however, M259 transactivated
only 5.2-fold. Another COOH-terminus deletion mutant,
CSX/NKX2.5(1-200), transactivated the reporter construct approxi-
mately 136-fold. Bars represent means ± SEM of at least three sepa-
rate transfection assays done in duplicate.
direct interaction with GATA4 (35). Because three of
group 2 mutation sites are within in the third helix
(Figure 3c), we examined whether these group 2 muta-
tion sites affect the association with GATA4. As
demonstrated in Figure 7, lane 1, [35S]-labeled wild-
type CSX/NKX2.5 associated with GATA4, but not
with GST alone (lane 6). Similar protein-protein inter-
actions with GATA4 were observed in all four group 2
mutants (lanes 2–5), but none of these proteins asso-
ciated with GST protein alone (lanes 7–10). These
results demonstrate that the missense mutations
found in group 2 patients do not significantly affect
the interaction with GATA4. Therefore, they poten-
tially sequester GATA4 from wild-type CSX/NKX2.5.
Discussion
Heterozygous mutations of the homeoprotein
CSX/NKX2.5 are associated with progressive AV
block with secundum ASD as well as several other
cardiac malformations that are transmitted as an
autosomal dominant trait (22, 23) In this study, we
examined the function of ten known mutations of
CSX/NKX2.5 found in patients in order to gain
insights into the nature and mechanism of the
molecular defects responsible for the clinical abnor-
malities. We were able to categorize these mutation
sites into five groups (Figure 1).
In spite of the extensive in vitro characterization of
these CSX/NKX2.5 mutations presented here, it is
not yet possible to define clear genotype-phenotype
associations. However, some generalizations are pos-
sible. For example, the M112 mutation (group 5)
abolished intron splicing (Figure 2c) and is likely to
function as loss of function allele in vivo, as the
mutant protein did not accumulate in transfected
cells (Figure 2d). Patients with M112 mutation show
second-degree AV block without morphological
defects, which is similar to the phenotype of hemizy-
gous Csx/Nkx2.5–null mice, who showed a high pen-
etrance of AV block and low incidence of ASD (20%)
without other morphological defects (M. Tanaka et
al., unpublished data). These findings suggest that a
loss of function of one allele may cause AV conduc-
tion delay but additional dominant effects of “hypo-
morphic” mutant proteins (groups 2 and 3) may
cause various anatomical anomalies such as ASD,
VSD, TOF, and left ventricular failure. (Note that
group 2 and 3 mutants have altered DNA binding
but preserved protein-protein interactions). In con-
trast, the patient with the M25 mutation (group 4,
25Arg-Cys missense mutation in the NH2-terminus),
exhibited VSD with TOF without AV block (Figure
1). In EMSA as well as in transient transfection
assays, M25 appeared to function similarly to the
wild-type CSX/NKX2.5 (Figures 4 and 5). Cotrans-
fection of plasmid encoding M25 and wild-type
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Figure 6
Inhibition of ANF-luciferase transcriptional activity of wild-type CSX/NKX2.5 by group 1, 2, and 3 mutants but not by group 4 mutant. (a)
Inhibition of transactivation of the ANF-luciferase reporter gene in the presence of both 1:1 and 2:1 ratio of M170, M189, M191, and M259
expression plasmid to wild-type expression plasmid. 10T1/2 cells were transiently transacted with 1.2 µg of ANF-luciferase(-638), 0.3 µg of
RSV–β-galactosidase, 0.7 µg of wild-type CSX/NKX2.5 expression plasmid, and 0.7 µg (hatched bars) or 1.4 µg (filled bars) of mutant expres-
sion plasmid or empty pcDNA3 plasmid to adjust the total amount of plasmid. A moderate reduction of luciferase activity was observed in
M170 mutants, and a further decrease of luciferase activity was detected in M189, M191, and M250 mutants. In contrast, M25 mutant
increased luciferase activity. Results are presented as a percent of the ANF reporter activity when cotransfected with wild-type and mutant
plasmid compared with that of the wild type alone (open bar). Bars represent means ± SEM of the means of at least three separate trans-
fection assays done in duplicate. (b) Protein-protein interaction of wild-type CSX/NKX2.5 with mutant proteins. MBP-fused wild-type
CSX/NKX2.5 protein was mixed with [35S]-labeled wild-type (lane 1) or ten mutants (lanes 2–11). After washing five times with binding
buffer, the protein complexes were resolved on SDS-PAGE and autoradiographed (top panel). Group 1 (lanes 2 and 3) and group 5 (lane
11) mutants did not associate with MBP-CSX/NKX2.5, whereas group 2, 3, and 4 mutants associated with MBP-CSX/NKX2.5 (lanes 4–10).
Fifty percent input of [35S]-labeled proteins are shown in the middle panel, and Coomassie blue–stained MBP-fused wild-type CSX/NKX2.5
proteins are shown in the bottom panel.
CSX/NKX2.5 increased the ANF luciferase activity,
which is different from other mutants examined (Fig-
ure 6a). Although, M25 is genetically a dominant
mutation vivo, our in vitro assays of CSX/NKX2.5
function is limited in explaining the nature of the
molecular defect of the M25 mutation.
Patients with the other eight mutations showed
both AV block and cardiac malformations (Figure 1).
Six mutations were found in the HD either as a non-
sense (M149 and M170 in group 2) or a missense
(M178, M188, M189, M191 in group 3) mutation. All
six HD mutant proteins had markedly reduced DNA
binding affinity (Figures 3 and 4). Even in the pres-
ence of two repeated CSX/NKX2.5 binding sites,
M149 and M170 (group 1) and M189 (group 2) did
not show any shifted bands (Figure 3, b and c). M178,
178Thr-Met mutation in between the second and third
helix, is likely to change the angle of the helix III,
resulting in the reduction of contact to the major
groove of DNA (10, 38, 39). Other group 2 mutations
were mapped in the third helix. Interestingly, two con-
served amino acids in the HD were mutated in
patients. 188Asn (51Asn in HD), which is conserved in
all members of the homeoprotein family and is
known to directly contact adenine in the major groove
of DNA (1), was mutated into Lys in M188 mutant,
resulting in markedly reduced DNA binding affinity
by more than 243-fold. Also, 191Tyr (54Tyr in HD),
which is conserved in all NK2 class homeoproteins
and is speculated to specify the DNA binding (4), was
mutated into Cys in M191, which reduced its DNA
binding affinity by 81-fold. Consistent with absent or
markedly reduced DNA binding, group 1 and 2
mutants had markedly reduced transcriptional activ-
ity on the ANF-luciferase reporter (Figure 5).
Previous studies in Xenopus demonstrated that
non–DNA-binding missense mutants act in a domi-
nant inhibitory manner on wild-type homeoproteins,
Mix1, XVent2, XNkx2.3, and XNkx2.5 (10, 38, 39). In
Mix1 HD proteins, the dominant inhibitory effect of
mutant proteins is likely due to their ability to homo-
or heterodimerize with other HD proteins, and these
mutant–wild-type homeoprotein complexes may
change the transcriptional activity (38). Accordingly,
we examined the homodimerization of
CSX/NKX2.5 and found that wild-type
CSX/NKX2.5 homodimerize on DNA that
contains two binding sites (Figure 3b). We
also demonstrated that CSX/NKX2.5 can
homodimerize without DNA by in vitro
pulldown assay (Figure 6b). All the group 2
mutations with a single missense mutations
in the HD had markedly reduced DNA bind-
ing (Figure 3c) but preserved dimerization
ability (Figure 6b). The mutants themselves
did not transactivate or suppress the ANF
promoter (Figure 5) but inhibited the tran-
scriptional activity of wild-type CSX/NKX2.5
(Figure 6a). However, the degree of inhibition
increased little by the increase in the wild-type versus
mutant plasmid from 1:1 to 1:2. This suggests that
the mutant may not simply act as a dominant
inhibitor of wild-type CSX/NKX2.5, but may inhibit
CSX/NKX2.5 function in a more complex manner.
The COOH-terminus deletion mutant of
CSX/NKX2.5(1-200) had a significantly increased tran-
scriptional activity on ANF promoter (136-fold) com-
pared to wild-type (23-fold). In contrast, two COOH-
terminus deletion mutants found in patients (group 3,
M198 and M259) exhibited similar (22-fold in M198)
or reduced (fivefold in M259) transcriptional activity.
This suggests that the region COOH-terminus to the
HD may contain several transcriptional activation and
repression domains, or the deletion mutations may
change the conformation of CSX/NKX2.5 to increase
or decrease transcriptional activity. Considering that
no mutations seen in patients showed higher tran-
scriptional activity than wild-type, it is possible that
constitutively active mutations may cause a different
phenotype or may even cause an embryonic lethal phe-
notype, therefore escaping clinical detection.
In summary, although nuclear localization was intact
in all mutants except M112, the mutations in the HD
(groups 1 and 2) results in the loss or severely impaired
DNA binding with the concomitant loss of their trans-
activation function. Mutations located outside of the
HD had normal DNA binding to the monomeric target
site but had reduced DNA binding to the dimeric target
site compared with wild-type CSX/NKX2.5. Group 2
mutations had preserved protein dimerization function
and exhibited an inhibitory function on wild-type
CSX/NKX2.5. Group 4 mutant with a single missense
mutations NH2-terminal to the HD acted very similar-
ly as the wild-type CSX/NKX2.5 except for subtle DNA
binding defect to the dimeric binding site. CSX/NKX2.5
is likely to form multifactor complexes to transactivate
target genes (34–37, 40), and these factors in each com-
plex could be different depending on the context of the
target sites. Through a complex mechanism,
CSX/NKX2.5 seems to regulate precisely target gene
activation and repression at each developmental stage.
Further analysis of target genes of CSX/NKX2.5 may
aid in the understanding of the role of the CSX/NKX2.5
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Figure 7
Interaction of group 2 mutants with GATA4 protein. [35S]-labeled wild-type
CSX/NKX2.5 and four group 2 mutant proteins were mixed with GST-GATA4
protein (lanes 1–5) or GST alone (lanes 6–10). Bound labeled proteins were
resolved on SDS-PAGE and autoradiographed (top panel). Fifty percent input
of [35S]-labeled proteins is also shown. Coomassie blue–stained GST-GATA4
(lanes 1–5) or GST (lanes 6–10) fusion proteins are shown (bottom panel).
in cardiac development as well as the genotype-pheno-
type associations resulting from its mutations.
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